Following last Friday's advance publication of the outcome of the case, the UK Supreme Court (UKSC) has today published the reasons for its decision in the long-running Actavis v. Eli Lilly case, ruling that Actavis's products infringe Lilly's patents in the UK, France, Italy and Spain. Lilly's patent concerns the safe and effective use of a cancer drug, pemetrexed, in co-therapy with vitamin B12. Actavis's proposed products differed only in relation to the salt form of the pemetrexed, it was argued. Actavis sought declarations of non-infringement in relation to the UK, French, German, Italian and Spanish patents in the UK courts. Actavis removed the German patent from the UK litigation in 2014. The Court of Appeal refused to grant the declarations sought by Actavis on the grounds that Actavis' proposed products would indirectly infringe Lilly's patent. However, the Court of Appeal found that the patent would not be directly infringed. Emma Fulton, one of the Hogan Lovells lawyers leading the case, commented: "Today's decision puts more emphasis on considering the invention in the patent when assessing whether a competitor infringes. It also brings UK law more closely in to line with the law in other key European countries." As well as overturning the Court of Appeal's decision on direct infringement, the Supreme Court has upheld the Court of Appeal's decision on indirect infringement.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.